.........................No adverse events reported from that trial so far, so hopefully CHM have got the CarT vs solid tumor problem solved................
CHM's Car-T therapy success against solid tumors would put CHM ahead of the pack and open up its medical treatment to an unbelievably huge market. Couldn't imagine what the SP could do but assume big pharma wouldn't allow CHM to separately license its therapy without an immediate T/O.
Elimination of chemo and radiation would be gladly welcomed by all patients and I would hope the whole medical profession.
- Forums
- ASX - By Stock
- CHM
- Ann: Second Dose Cohort Initiated in CLTX CAR T Phase 1 Trial
CHM
chimeric therapeutics limited
Add to My Watchlist
12.5%
!
0.5¢

Ann: Second Dose Cohort Initiated in CLTX CAR T Phase 1 Trial, page-36
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.5¢ |
Change
0.001(12.5%) |
Mkt cap ! $8.060M |
Open | High | Low | Value | Volume |
0.4¢ | 0.5¢ | 0.4¢ | $3.336K | 821.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 2421939 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 18599873 | 22 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 2421939 | 0.004 |
41 | 27362937 | 0.003 |
16 | 15400505 | 0.002 |
12 | 54600000 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 18599873 | 22 |
0.006 | 13884684 | 16 |
0.007 | 3100000 | 2 |
0.008 | 8542434 | 6 |
0.009 | 2327672 | 4 |
Last trade - 10.26am 26/06/2025 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |
The Watchlist
3DA
AMAERO LTD
Hank Holland, Chairman & CEO
Hank Holland
Chairman & CEO
Previous Video
Next Video
SPONSORED BY The Market Online